Treats relapsing forms of multiple sclerosis (MS). ANDA 209639, held by Biocon Pharma. Teriflunomide.
As of Nov 16, 2026, ANDA 209639 (Teriflunomide), held by Biocon Pharma, was first approved by FDA on Mar 13, 2023, with 1 approved supplement and 0 published complete response letters.
Teriflunomide tablet is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 2023 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Dec 20, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 13, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters